#ASCO2022 Destiny-04. ILD as expected. My thoughts: best in show for breast cancer this year. HER2-low now on the table for ADCs as a class. There is an accompanying NEJM paper. The audience goes wild in a way I have not seen since the HER2 2005 rock concert. Congrats to Dr Modi.